A urine-based methylation signature for risk stratification within low-risk prostate cancer

T. A. Jatkoe, Robert Jeffrey Karnes, S. J. Freedland, Y. Wang, A. Le, J. Baden

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Prostate cancer overdiagnosis and overtreatment represents a major problem. Many men with low-grade disease on biopsy are undergraded and they harbour high-grade disease at prostatectomy with no reliable way to identify these men. We used a novel urine-based 2-gene methylation test to identify prostate cancers with aggressive features.

METHODS: Following a proof of concept study in 100 post-radical prostatectomy tissue samples, urine samples were tested from 665 men at multiple U.S. centers undergoing prostate needle biopsy for elevated prostate-specific antigen (2-10 ng ml(-1)). A prediction model was then developed from a combination of clinical factors and the urine-based markers. It was then prospectively tested for accurate prediction of adverse disease (surgical Gleason score ⩾7 and/or a pathological stage ⩾T3a) using urine from a separate cohort of 96 men before radical prostatectomy.

RESULTS: Among pre-prostatectomy men with a biopsy Gleason score <7, 41% had adverse disease of which 100% were correctly identified by the test with a negative predictive value of 100% (95% confidence interval, 86-100%).

CONCLUSIONS: This urine-based test accurately identifies men with clinical low-risk disease who do not have adverse pathology in their prostates and would be excellent candidates for active surveillance.

Original languageEnglish (US)
Pages (from-to)802-808
Number of pages7
JournalBritish Journal of Cancer
Volume112
Issue number5
DOIs
StatePublished - Mar 3 2015

Fingerprint

Methylation
Prostatic Neoplasms
Urine
Prostatectomy
Neoplasm Grading
Prostate
Biopsy
Needle Biopsy
Prostate-Specific Antigen
Confidence Intervals
Pathology
Genes
Medical Overuse

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A urine-based methylation signature for risk stratification within low-risk prostate cancer. / Jatkoe, T. A.; Karnes, Robert Jeffrey; Freedland, S. J.; Wang, Y.; Le, A.; Baden, J.

In: British Journal of Cancer, Vol. 112, No. 5, 03.03.2015, p. 802-808.

Research output: Contribution to journalArticle

Jatkoe, T. A. ; Karnes, Robert Jeffrey ; Freedland, S. J. ; Wang, Y. ; Le, A. ; Baden, J. / A urine-based methylation signature for risk stratification within low-risk prostate cancer. In: British Journal of Cancer. 2015 ; Vol. 112, No. 5. pp. 802-808.
@article{ce069638afff49599d7f23e86aac6ba8,
title = "A urine-based methylation signature for risk stratification within low-risk prostate cancer",
abstract = "BACKGROUND: Prostate cancer overdiagnosis and overtreatment represents a major problem. Many men with low-grade disease on biopsy are undergraded and they harbour high-grade disease at prostatectomy with no reliable way to identify these men. We used a novel urine-based 2-gene methylation test to identify prostate cancers with aggressive features.METHODS: Following a proof of concept study in 100 post-radical prostatectomy tissue samples, urine samples were tested from 665 men at multiple U.S. centers undergoing prostate needle biopsy for elevated prostate-specific antigen (2-10 ng ml(-1)). A prediction model was then developed from a combination of clinical factors and the urine-based markers. It was then prospectively tested for accurate prediction of adverse disease (surgical Gleason score ⩾7 and/or a pathological stage ⩾T3a) using urine from a separate cohort of 96 men before radical prostatectomy.RESULTS: Among pre-prostatectomy men with a biopsy Gleason score <7, 41{\%} had adverse disease of which 100{\%} were correctly identified by the test with a negative predictive value of 100{\%} (95{\%} confidence interval, 86-100{\%}).CONCLUSIONS: This urine-based test accurately identifies men with clinical low-risk disease who do not have adverse pathology in their prostates and would be excellent candidates for active surveillance.",
author = "Jatkoe, {T. A.} and Karnes, {Robert Jeffrey} and Freedland, {S. J.} and Y. Wang and A. Le and J. Baden",
year = "2015",
month = "3",
day = "3",
doi = "10.1038/bjc.2015.7",
language = "English (US)",
volume = "112",
pages = "802--808",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A urine-based methylation signature for risk stratification within low-risk prostate cancer

AU - Jatkoe, T. A.

AU - Karnes, Robert Jeffrey

AU - Freedland, S. J.

AU - Wang, Y.

AU - Le, A.

AU - Baden, J.

PY - 2015/3/3

Y1 - 2015/3/3

N2 - BACKGROUND: Prostate cancer overdiagnosis and overtreatment represents a major problem. Many men with low-grade disease on biopsy are undergraded and they harbour high-grade disease at prostatectomy with no reliable way to identify these men. We used a novel urine-based 2-gene methylation test to identify prostate cancers with aggressive features.METHODS: Following a proof of concept study in 100 post-radical prostatectomy tissue samples, urine samples were tested from 665 men at multiple U.S. centers undergoing prostate needle biopsy for elevated prostate-specific antigen (2-10 ng ml(-1)). A prediction model was then developed from a combination of clinical factors and the urine-based markers. It was then prospectively tested for accurate prediction of adverse disease (surgical Gleason score ⩾7 and/or a pathological stage ⩾T3a) using urine from a separate cohort of 96 men before radical prostatectomy.RESULTS: Among pre-prostatectomy men with a biopsy Gleason score <7, 41% had adverse disease of which 100% were correctly identified by the test with a negative predictive value of 100% (95% confidence interval, 86-100%).CONCLUSIONS: This urine-based test accurately identifies men with clinical low-risk disease who do not have adverse pathology in their prostates and would be excellent candidates for active surveillance.

AB - BACKGROUND: Prostate cancer overdiagnosis and overtreatment represents a major problem. Many men with low-grade disease on biopsy are undergraded and they harbour high-grade disease at prostatectomy with no reliable way to identify these men. We used a novel urine-based 2-gene methylation test to identify prostate cancers with aggressive features.METHODS: Following a proof of concept study in 100 post-radical prostatectomy tissue samples, urine samples were tested from 665 men at multiple U.S. centers undergoing prostate needle biopsy for elevated prostate-specific antigen (2-10 ng ml(-1)). A prediction model was then developed from a combination of clinical factors and the urine-based markers. It was then prospectively tested for accurate prediction of adverse disease (surgical Gleason score ⩾7 and/or a pathological stage ⩾T3a) using urine from a separate cohort of 96 men before radical prostatectomy.RESULTS: Among pre-prostatectomy men with a biopsy Gleason score <7, 41% had adverse disease of which 100% were correctly identified by the test with a negative predictive value of 100% (95% confidence interval, 86-100%).CONCLUSIONS: This urine-based test accurately identifies men with clinical low-risk disease who do not have adverse pathology in their prostates and would be excellent candidates for active surveillance.

UR - http://www.scopus.com/inward/record.url?scp=84928696411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928696411&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.7

DO - 10.1038/bjc.2015.7

M3 - Article

C2 - 25695483

AN - SCOPUS:84928696411

VL - 112

SP - 802

EP - 808

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -